Chini Bice

University Consiglio Nazionale delle Ricerche
Department Institute of Neuroscience
Biographical Info


1987  MD cum laude, Medical School, University of Milan 1992  PhD in Biotechnology Applied to Pharmacology and Cellular and Molecular Biotechnologies University  of Milan

Professional career

1992- 1993    Research Associate The Salk Institute, La Jolla, USA 1993 -1995    Research Associate    CCIPE - CNRS/INSERM, Montpellier, France Since 1995    Group leader at the CNR Institute of Neuroscience, Milan, Italy Since 1997    CNR Researcher leader at the CNR Institute of Neuroscience, Milan, Italy (Permanent position) Since 2008    CNR First Reseacher Since 2019    CNR Director of Research   2014  National Scientific Habilitation - Full Professor in Biochemistry (05/E1) 2019  National Scientific Habilitation - Full Professor in Pharmacology (05/G1

Research topics: Molecular pharmacology of neuropeptide and neuropeptide receptors.

The main goal of the laboratory is to characterize the neurochemical basis of oxytocin and vasopressin signalling. These two neuropeptides paly a crucial role in shaping the social brain and are promising new traget for several neurodevelopmental and psychiatric conditions such as autism and schizophrenia.

1) Oxytocin and vasopressin receptors as prototypes of G-protein coupled receptors.

The laboratory is focused on the molecular and cellular pharmacology of oxytocin and vasopressin receptors, including drug design, binding and signalling properties of specific ligands, structure function studies for the identification of the conformational states underlying receptor activation and inactivation, confocal and video imaging analysis of receptor localization and trafficking.

2) Oxytocin and vasopressin in brain disorders:

In the last years, the range of topics and techniques has expanded to include neurobiological studies of oxytocin/vasopressin involvement in autism, Prader-Willi syndrome and schizophrenia. By combining neurochemical, anatomical and behavioral approaches in vitro and in vivo, our  final goal is to develop new pharmacological analogues of potential clinical use in neurodevelopmental and psychiatric disorders

Ongoing Grant support

2019-2020     Fritz Thyssen Foundation (Role: PI) 2020-2023     Telethon grant GGP19103   (Role: PI)

Technology transfer and industrial activity

2011  co-founder of the spin off company Proxentia, whose mission is to develop a proprietary label-free technology for the detection of biomeolecular interactions. In 2015 Proxentia has won a SME Instrument grant in the H2020 program of the European Community ( )

Teaching activity

2002- 2006     Pharmacology, Medical School, San Raffaele University, Milan 2004 -2005     Pharmacology, Biotechnology School, San Raffaele Univ, Milan 2004- 2009     Pharmacogenomics, Faculty of Science, Univ of Milan Since 2016     Pharmacology, Medical School, Humanitas University, Milan
Laboratories Neurobiology of oxytocin and vasopressin receptors